Jadenu (deferasirox) — United Healthcare
Chronic iron overload due to blood transfusions (transfusional hemosiderosis)
Initial criteria
- Diagnosis of chronic iron overload (e.g., sickle cell anemia, thalassemia, etc.) due to blood transfusion
Reauthorization criteria
- Documentation of positive clinical response to Exjade or Jadenu therapy
Approval duration
12 months